Risankizumab.rzaa: an interleukin monoclonal antibody antagonist binding to the p19 subunit of human IL-23 cytokine.
David M. Paton
págs. 605-613
Sarecycline hydrochloride for the treatment of acne vulgaris.
Grace Kaul, D. Saxena, Arunava Dasgupta, Sidharth Chopra
págs. 615-625
Viltolarsen for the treatment of Duchenne muscular dystrophy
R. R. Roshmi, Toshifumi Yokota
págs. 627-639
Targeted therapies for ROS1-rearranged non-small cell lung cancer.
Tejas Patil, E. Simons, Rao Mushtaq, Jose M. Pacheco, Robert C. Doebele, Daniel W. Bowles
págs. 641-652
The 2019 TOPRA (Organization for Professionals in Regulatory Affairs) Annual Symposium (September 30-October 2, 2019 – Dublin, Ireland)
A. Falcone, J. Fernández
págs. 653-659
New product intros [amlodipine benzoate (new formulation), beperminogene perplasmid, canagliflozin (new indication), drospirenone, immune globulin intravenous, lefamulin, netakimab, nintedanib (new indication), quizartinib, ravulizumab-cwvz (new indication), segesterone acetate /ethinylestradiol (new combination), tegoprazan)].
págs. 661-664
© 2001-2024 Fundación Dialnet · Todos los derechos reservados
Coordinado por: